<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/7369E051-ECFC-4808-A044-651879C318D1"><gtr:id>7369E051-ECFC-4808-A044-651879C318D1</gtr:id><gtr:name>MRC Cancer Cell Unit</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB2 2XZ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7369E051-ECFC-4808-A044-651879C318D1"><gtr:id>7369E051-ECFC-4808-A044-651879C318D1</gtr:id><gtr:name>MRC Cancer Cell Unit</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB2 2XZ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CD15F044-71F1-4444-8FAA-ABA0A5102150"><gtr:id>CD15F044-71F1-4444-8FAA-ABA0A5102150</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Ko Ferrigno</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U105359876"><gtr:id>B23FADBF-89AF-4CD9-9C72-1841A3108BCE</gtr:id><gtr:title>Peptide aptamers</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U105359876</gtr:grantReference><gtr:abstractText>The drug discovery process faces two problems. The first is determining which processes in a diseased cell can be used safely as drug targets. In cancer, for example, one wishes to kill tumour cells while safeguarding neighbouring healthy cells. The second problem is the identification of drugs that bind to the chosen target.||To address these problems, we are developing strategies that allow the rapid and inexpensive identification of peptides -- component parts of proteins -- that bind tightly to other proteins in cancer cells. This involves collaborations with physicists familiar with techniques from the semi-conductor industry, with whom we have shown that transistors can be used to detect interactions between disease proteins and our peptides. This new technology is likely to impact the processes of diagnosis and prognosis as well as identifying new drug targets.||Because peptides are modular components that combine to make up the proteins that perform the majority of a cells tasks, we can use our peptides to create tools that work inside cells to manipulate the initial target. Peptides are also small enough to be used as a starting point in drug design. Using our technology, we have shown that inhibition of a protein called BCL-6 prevents the growth of lymphoma cells. We have since implicated BCL-6 in other cancers, such as those of the bladder and the breast and we are now asking whether our inhibitor is likely to be effective in these cancers. We are seeking ways to turn this peptide into a drug that will be of direct benefit to patients.</gtr:abstractText><gtr:technicalSummary>We develop technologies for the rapid identification and validation of cancer biomarkers, and apply our tools to validate novel markers as drug targets. Our technology centres on peptide aptamers, engineered proteins that are conceptually similar to antibodies, but are much more robust. One valuable aspect of this is that the peptide aptamer that recognises a protein biomarker in a cell lysate or patient biopsy can be used to study the role of its target protein in models of biology and of disease. Where the peptide aptamer is able to ameliorate a disease phenotype in vitro, the same peptide aptamer becomes a basis for drug discovery efforts.||The biomarker discovery platform involves the spotting of nanolitres of multiple peptide aptamers on modified microscope slides to create a protein microarray. We have shown that these can detect the expression of human papilloma virus proteins specifically in infected cells. This experiment used the current state-of the-art technology, which involves the labelling of all the proteins in a control (normal) cell lysate with one fluorescent dye, and all of the proteins in the test (disease) lysate with another. This allows us to optically detect the specific recruitment of proteins from the infected cell to given peptide aptamer spots in a multiplexed array- our most complicated array to date had close to 5000 spots on each slide. To our knowledge, our array is the first to work robustly in the detection of target proteins in human cell lysates.||A weakness of this approach is that it requires the covalent labelling of the sample proteins, which will result in the loss of biological information encoded in the three-dimensional folding of each protein in a cell. To overcome this, we collaborate with chemists, physicists and engineers in developing label-free detection of protein-protein interactions in microarray format, using detection methods that can capitalise on the inexpensive, massively parallel synthesis methods of the semi-conductor industry. Here again, we are able to detect specific proteins in complex cell lysates, although so far we have not attempted to work with systems of complexity greater than 10,000 proteins.||With regard to the second major strand- drug discovery- we have used peptide aptamers to validate the transcriptional repressor BCL-6 as a drug target in lymphoma, and have since shown that the protein is over-expressed in breast, colorectal and bladder cancer cells, indicating that it may also play a role there. Mapping the binding of our peptide aptamer to BCL-6 has revealed a novel protein interaction surface of 18 amino acid residues, the centre of which defines the opening to a druggable pocket within BCL-6. Our data indicate that the flexibility afforded by this pocket is required for BCL-6 to be able to mediate the assembly of a transcriptional repressor complex at target promoters, suggesting that small molecules that bind within and stabilise this pocket would inhibitBCL-6 function, allowing the de-repression of target promoters including that of p53. We are in the process of developing a homogenous in vitro assay for peptide aptamer binding to BCL-6 that can be used for small molecules that bind in this pocket.</gtr:technicalSummary><gtr:fund><gtr:end>2007-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2001-07-16</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>446666</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Electronic and Electrical Engineering Leeds</gtr:department><gtr:description>Label free protein detection- Walti</gtr:description><gtr:id>BB0C3611-06EB-4053-8E71-B2EB090375C2</gtr:id><gtr:impact>Papers with Walti as co-author in section 1. Joint award of Top50 Nano awards for 2008. Patent filing. This is a multi-disciplinary collaboration- Walti and colleagues are mostly physicists. Collaborations also includes chemists in Oxford (Davis- see separate entry).</gtr:impact><gtr:outcomeId>JEsYVMn7Eug-1</gtr:outcomeId><gtr:partnerContribution>New understanding of surface chemistry, interactions between proteins and inorganic surfaces, several papers</gtr:partnerContribution><gtr:piContribution>Defined the problem, provided the reagents, designed the experiments, engaged electronic engineers and physicists with the research question.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Engineering</gtr:department><gtr:description>Label free protein detection- Migliorato</gtr:description><gtr:id>6B4C8F86-7DEA-4C4B-8AEE-0004C0B1D743</gtr:id><gtr:impact>Papers with Estrela as first author. Migliorato's group have filed patents to which we did not contribute inventively. This was a multi-disciplinary collaboration.</gtr:impact><gtr:outcomeId>fP2K9oCaUud-1</gtr:outcomeId><gtr:partnerContribution>A better understanding of protein behaviour on inorganic surfaces.</gtr:partnerContribution><gtr:piContribution>Defined the research problem, engaged the chemists and physicists with the biological goals, educated them about proteins, protein chemistry and protein stability, provided reagents, designed experiments, helped with grant writing and paper drafting</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F59A9B40-8DFC-4838-A4C0-6A106E06CBC5</gtr:id><gtr:title>A peptide aptamer to antagonize BCL-6 function.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a40f6146bc763df4fc9b0ed32e4892b"><gtr:id>0a40f6146bc763df4fc9b0ed32e4892b</gtr:id><gtr:otherNames>Chattopadhyay A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>YRJq6GBnXGQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91510C88-3C1B-4E37-ABE1-AA7607050F0E</gtr:id><gtr:title>Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80ae49d2103cb99b9ecd5da3c0cea07f"><gtr:id>80ae49d2103cb99b9ecd5da3c0cea07f</gtr:id><gtr:otherNames>Noton EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>hZ3ZwacF64U</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5467A134-065A-4DC2-B801-C61A25823D4F</gtr:id><gtr:title>Structure-function studies of an engineered scaffold protein derived from stefin A. I: Development of the SQM variant.</gtr:title><gtr:parentPublicationTitle>Protein engineering, design &amp; selection : PEDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3428caf64f2f1ba6dfa8503bea86a476"><gtr:id>3428caf64f2f1ba6dfa8503bea86a476</gtr:id><gtr:otherNames>Hoffmann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1741-0126</gtr:issn><gtr:outcomeId>tdzYTDHiJFs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41B44113-57CE-45D0-B449-C7EA2139F5A8</gtr:id><gtr:title>Label-free electrical detection of DNA hybridization for the example of influenza virus gene sequences.</gtr:title><gtr:parentPublicationTitle>Analytical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7141154b3dc57cabafa5164e97c370df"><gtr:id>7141154b3dc57cabafa5164e97c370df</gtr:id><gtr:otherNames>Kukol A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-2697</gtr:issn><gtr:outcomeId>Rbb8vppYp2f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>515CB464-1DD1-493E-A8CC-95E2206B4911</gtr:id><gtr:title>Peptide aptamers as new tools to modulate clathrin-mediated internalisation--inhibition of MT1-MMP internalisation.</gtr:title><gtr:parentPublicationTitle>BMC cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0032a14eaa46173890236dca2399a631"><gtr:id>0032a14eaa46173890236dca2399a631</gtr:id><gtr:otherNames>Wickramasinghe RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-2121</gtr:issn><gtr:outcomeId>esaj1HXYVNu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A55F7581-253C-4923-A72A-CA5D8AC47EA3</gtr:id><gtr:title>Development of peptide aptamer microarrays for detection of HPV16 oncoproteins in cell extracts.</gtr:title><gtr:parentPublicationTitle>Analytical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/538b6b2857a606b83c6e40227361d780"><gtr:id>538b6b2857a606b83c6e40227361d780</gtr:id><gtr:otherNames>Laurenson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-2697</gtr:issn><gtr:outcomeId>oiRq2zVCyaq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13B2DB4F-4551-4FF5-BEA4-EC6369FCCC1C</gtr:id><gtr:title>Highly specific label-free protein detection from lysed cells using internally referenced microcantilever sensors.</gtr:title><gtr:parentPublicationTitle>Biosensors &amp; bioelectronics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38c13993c9d43cc666bbe8811eb14f83"><gtr:id>38c13993c9d43cc666bbe8811eb14f83</gtr:id><gtr:otherNames>Shu W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0956-5663</gtr:issn><gtr:outcomeId>VUA1jt3KGWJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EC8B758-E7BB-4AB0-B992-C06EBE1AF94B</gtr:id><gtr:title>Surface-immobilized peptide aptamers as probe molecules for protein detection.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/353e752deb089a0d0e572cf98e705365"><gtr:id>353e752deb089a0d0e572cf98e705365</gtr:id><gtr:otherNames>Johnson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>HXCMT2nrMJj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BEF5C11-1FE3-459D-B101-AFC0238EE61C</gtr:id><gtr:title>Peptide aptamers in label-free protein detection: 1. Characterization of the immobilized scaffold.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3e1621d54de82894ba12a9771e5e30c"><gtr:id>a3e1621d54de82894ba12a9771e5e30c</gtr:id><gtr:otherNames>Davis JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>qgeyrpQXnKf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF50AF06-4EA6-4BD4-9524-A5CD0B4099E8</gtr:id><gtr:title>Electrical protein detection in cell lysates using high-density peptide-aptamer microarrays.</gtr:title><gtr:parentPublicationTitle>Journal of biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e02a907747d385859de5a8346fba086"><gtr:id>7e02a907747d385859de5a8346fba086</gtr:id><gtr:otherNames>Evans D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1475-4924</gtr:issn><gtr:outcomeId>KnTPL2ptWGi</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U105359876</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>